Baraclude - After Plavix, Baraclude is the next significant challenge that BMS will have to face immediately.

FORBES: Looking At Bristol-Myers Squibb's Major Patent Expiries That Will Drag On Growth

Baraclude is approved in the United States to treat patients with chronic hepatitis B in adults who have active virus and liver damage.

FORBES: Bristol-Myers Squibb Hit With Surprise Patent Loss

Entecavir is the active ingredient in Baraclude.

FORBES: Bristol-Myers Squibb Hit With Surprise Patent Loss

For the moment, this is a possible take away from a surprising loss the drugmaker suffered this week in a federal court, where a judge ruled that this sort of patent on its Baraclude treatment for hepatitis B is invalid.

FORBES: Not So Obvious: A Bristol-Myers Patent Defeat May Change Wall Street Views